AstraZeneca and Daiichi Sankyo’s Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy, according to data presented on Sunday.
Diagnostic companies are racing to develop tests for monkeypox, hoping to tap into a new market as governments ramp up efforts to trace the world’s first major outbreak of the viral infection outside of Africa.
Shares of Repare Therapeutics soared more than 27 percent in premarket trading on June 2 following the previous day’s announcement of a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
The long weekend saw three established drugs developed by Bristol Myers Squibb, Novartis, and Roche score new approvals from the U.S. Food and Drug Administration.
Genentech, a member of the Roche group, announced new data on Thursday related to the company’s investigational CD20xCD3 T-cell engaging bispecific antibody glofitamab, which is intended to treat relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
As cases and news of monkeypox spread globally, scientists are investigating the unprecedented outbreak. BioSpace compiled updates about tracking, origins and treatments concerning monkeypox.
Roche on Wednesday said the company and its unit have developed three test kits to detect the monkeypox virus, as the disease spreads in regions outside Africa, where the virus is not normally found.